FMR1 and fragile X syndrome: In our study, the results indicate that miR-129-5p could negatively regulate the expression level of FMRP and is responsible for aberrant neuronal migration, and antagonising miR-129-5p may serve as a new therapeutic strategy for treating Fragile X syndrome.